ALX Oncology Holdings Inc (ALXO)
13.77
-0.89
(-6.07%)
USD |
NASDAQ |
May 20, 16:00
13.77
0.00 (0.00%)
After-Hours: 17:39
ALX Oncology Holdings Cash from Investing (TTM): 28.84M for March 31, 2024
Cash from Investing (TTM) Chart
Historical Cash from Investing (TTM) Data
| Date | Value |
|---|---|
| March 31, 2024 | 28.84M |
| December 31, 2023 | 44.66M |
| September 30, 2023 | 72.26M |
| June 30, 2023 | 73.14M |
| March 31, 2023 | -9.20M |
| December 31, 2022 | -235.42M |
| September 30, 2022 | -250.88M |
| June 30, 2022 | -264.97M |
| March 31, 2022 | -188.84M |
| Date | Value |
|---|---|
| December 31, 2021 | -4.923M |
| September 30, 2021 | -0.416M |
| June 30, 2021 | 0.613M |
| March 31, 2021 | 0.613M |
| December 31, 2020 | 0.61M |
| September 30, 2020 | 0.683M |
| June 30, 2020 | 0.052M |
| March 31, 2020 | -0.245M |
| December 31, 2019 | -0.353M |
Cash From Investing Definition
Cash from Investing is a major line item of the statement of cash flows. This metric tracks the movement of cash flows for the overall investing activities of the company. A few examples of investing activities include net change in PP&E, and net divestitures.
Cash from Investing (TTM) Range, Past 5 Years
-264.97M
Minimum
Jun 2022
73.14M
Maximum
Jun 2023
-40.76M
Average
-0.0965M
Median
Cash from Investing (TTM) Benchmarks
| Bristol-Myers Squibb Co | -21.70B |
| Nurix Therapeutics Inc | 87.75M |
| Exelixis Inc | 134.43M |
| Geron Corp | 32.62M |
| Verastem Inc | -12.66M |